Knowledge Center
Topic
Clear
Close
13.04.2021
When and why should my API be a new crystalline polymorph, amorphous, a co-crystal, or an alternative salt?
When and why should my API be a new crystalline polymorph, amorphous, a co-crystal, or an alternative salt?
17.08.2020
Teva api Adopts New Nitrosamine Regulations
Teva api Adopts New Nitrosamine Regulations
10.08.2020
Navigating China’s API Regulations
Navigating China’s API Regulations
24.06.2020
Creatively using co-crystals to produce alternative generic products
Creatively using co-crystals to produce alternative generic products
31.10.2019
Teva api Offers New API Sterilization Services
Teva api Offers New API Sterilization Services
11.09.2019
EcoVadis assessment
EcoVadis assessment
07.04.2019
A global API supplier that understands the API industry!
A global API supplier that understands the API industry!
29.01.2019
Trends in the API industry that you should be aware of (2019)
Trends in the API industry that you should be aware of (2019)
04.11.2018
Why changes in the API manufacturing landscape is great news for Teva api
Why changes in the API manufacturing landscape is great news for Teva api
Last site inspections
- Feb 17-21, 2020 Teva API had a successful inspection in the Teva api Italy, Rho site by AIFA
- Feb 11-14, 2020 Teva API had a successful inspection in the Teva api India, Malanpur site by PMDA
- Jan 20-24, 2020 Teva API had a successful inspection in the Teva api Croatia site by USFDA
Last regulatory updates
- Sep 13, 2021 CEP
- Jun 13, 2021 CEP
- May 01, 2021 EU DMF